Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Secures $170 Million in Private Placement Equity Financing
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Key Management Appointments
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Participate in Upcoming Healthcare Conferences
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Shares Key Milestones and Business Updates for 2022
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Present at the 5th Annual Cowen IO Next Summit
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
News headline image
2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.